Intrinsic Therapeutics Names Keith Valentine President and Chief Executive Officer

April 11, 2025

BOSTON, MA—Intrinsic Therapeutics, a medical technology company changing the standard care for lumbar discectomy patients, has appointed Keith Valentine as President and Chief Executive Officer effective May 2025.

  • Valentine brings 30+ years of spine industry leadership experience to the company.
  • Valentine’s appointment comes at a strategic time with Barricaid’s CPT-1 code becoming effective in January 2026, positioning the company to expand its market for its annular closure device that reduces re-herniations by 81%.
  • Board Chairman Ryan Drant praised Valentine’s track record in commercializing spinal implants while acknowledging outgoing leader Cary Hagan’s decade of leadership through key milestones including Barricaid’s PMA approval.

Intrinsic is the developer of the FDA-approved Barricaid implant for annular closure, which is designed to reduce the rate of re-herniation and re-operation following discectomy.